Adeno-Associated Viral Vectors Market Research, Outlook,

“The Business Research Company recently published a comprehensive report on global Adeno-associated viral vectors market size and trends analysis with forecast 2024-2033. This latest market research report provides a wealth of valuable insights and data, including global market size and competitors' regional shares and market shares. It also covers current trends, future opportunities and essential data for success in the industry.

Ready to dive into something exciting? Get your free exclusive sample of our research report @

https://www.thebusinessresearchcompany.com/sample.aspx?id=15969&type=smp

According to The Business Research Company, the market size for adeno-associated viral vectors has grown rapidly in recent years. It will grow from $2.29 billion in 2023 to $2.69 billion in 2024, at a compound annual growth rate (CAGR) of 17.6%. The growth over the historical period is due to vaccine development, increased funding and investment, academic and industry collaborations, expansion of clinical trials, and public awareness and advocacy.

The adeno-associated viral vector market is expected to witness rapid growth in the next few years. In 2028, it will grow to $5.17 billion at a compound annual growth rate (CAGR) of 17.7%. The growth during the forecast period is due to expansion of therapeutic applications, increasing prevalence of genetic and neurological disorders, regulatory approvals and support, and cost reductions in manufacturing. Key trends during the forecast period include advancements in gene therapy, technological innovations, scalable manufacturing processes, collaborations and investments, and technological advances.

Get the full scope of the report @

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Market drivers and trends:

The increasing prevalence of genetic disorders is expected to drive the growth of the adeno-associated viral vectors market. Genetic disorders are diseases caused by abnormalities in a person's DNA, resulting in physical or developmental abnormalities. Improved diagnostic techniques, greater awareness and older reproductive age, together with environmental factors and genetic drift, are leading to an increase in the prevalence of genetic disorders. Adeno-associated viral vectors are used in gene therapy for genetic disorders, delivering corrective genes into target cells to potentially treat diseases such as muscular dystrophy or cystic fibrosis. For example, as of February 2023, congenital diseases caused an estimated 240,000 deaths of babies worldwide within 28 days of birth each year, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health. Another 170,000 children between the ages of one month and five years die as a result of congenital diseases. Therefore, increasing prevalence of genetic disorders is driving the market for adeno-associated viral vectors.

Major companies operating in the adeno-associated viral vector market are focusing on offering replication capsid plasmids off-the-shelf to gain a competitive advantage in the market. Rep/Cap plasmids, commonly used in gene therapy for the production of adeno-associated virus (AAV) vectors, are available from numerous commercial suppliers tailored to the needs of molecular biology research. For example, in January 2024, Charles River Laboratories International Inc., a US-based pharmaceutical company, introduced a series of off-the-shelf replication capsid plasmids that streamline AAV-based gene therapy initiatives. This expansion of their product portfolio complements existing offerings of lentiviral packaging and AAV helper plasmids and reduces manufacturing costs by up to 66%. These ready-to-use plasmids undergo batch production with careful documentation that conforms to CMC guidelines and is accompanied by a Certificate of Analysis (COA) to facilitate the submission of IND and Clinical Trial Applications (CTA).

Key benefits for stakeholders:

• Comprehensive market insights: Stakeholders gain access to detailed market statistics, trends and analysis that help them understand the current and future landscape of their industry.
• Informed decision making: Reports provide critical data to support strategic decisions, reduce risk and improve business planning.
• Competitive Advantage: With detailed competitive analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company provides customized reports tailored to specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global perspective: Reports cover various regions and markets, providing a comprehensive overview that helps stakeholders expand and operate successfully on a global scale.

Key Market Players:

Pfizer Inc., Astellas Pharma, Biogen Inc., Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics, Ultragenyx Pharmaceutical, Amicus Therapeutics Inc., Oxford Biomedica, Asklepios BioPharmaceutical Inc., uniQure biopharma BV , Spark Therapeutics Inc., Akouos Inc., Adverum Biotechnologies Inc., Passage Bio Inc., AVROBIO Inc, MeiraGTx Holdings plc, GenSight Biologics SA, Freeline Therapeutics, Aspa Therapeutics Inc., Adrenas Therapeutics Inc., 4D Molecular Therapeutics, Abeona Therapeutics Inc., Neurophth Therapeutics

Key Insights on Adeno-Associated Viral Vectors Market 2024:

• The adeno-associated viral vector market is expected to witness rapid growth in the next few years. In 2028, it will grow to $5.17 billion at a compound annual growth rate (CAGR) of 17.7%.
• Rising prevalence of genetic disorders fuels growth in adeno-associated viral vectors market
• Advances in commercial Rep/Cap plasmids
• North America was the largest region in the adeno-associated viral vector market in 2023

We offer customized reports. Click @

https://www.thebusinessresearchcompany.com/Customise?id=15969&type=smp

Contact us:
The economic research company
Europe: +44 207 1930 708
Asia: +91 88972 63534
America: +1 315 623 0293
Email: [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Health blog: https://healthcareresearchreports.com/
Global market model: https://www.thebusinessresearchcompany.com/global-market-model

Find out more about the business research company

The economic research company (www.thebusinessresearchcompany.com) is a leading market research firm known for its expertise in business, market and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals and technology, providing unparalleled insight and strategic advice to clients worldwide.

This press release was published on openPR.